CALCA(83-119) binds CALCA antibodies

Stable Identifier
Reaction [binding]
Homo sapiens
Locations in the PathwayBrowser
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout
The sensory neuropeptide calcitonin gene-related peptide 1 (CALCA(83-119), aka CGRP) plays an important role in primary headaches. Monoclonal antibodies against CALCA(83-119) are effective in migraine treatment (Edvinsson 2018). Humanised IgG monoclonal antibodies such as fremanezumab (TEV-48125) (Bigal et al. 2015, Silberstein et al. 2017), galcanezumab (LY2951742) (Skljarevski et al. 2018, Spindler & Ryan 2020) and eptinezumab (Dodick et al. 2014, Dhillon 2020) have been developed as alternatives to CALCR antagonists (such as telcagepant). They show they can effectively reduce migraine headache and inhibit neurogenic vasodilation in humans. These antibodies have the advantage of longer half-lives compared to small molecule antagonists and fewer toxic side-effects.
Literature References
PubMed ID Title Journal Year
29171818 Fremanezumab for the Preventive Treatment of Chronic Migraine

Goadsby, PJ, Silberstein, SD, Blankenbiller, T, Ma, Y, Yeung, PP, Dodick, DW, Bigal, ME, Yang, R, Aycardi, E, Grozinski-Wolff, M

N. Engl. J. Med. 2017
32266704 Eptinezumab: First Approval

Dhillon, S

Drugs 2020
26432182 Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study

Newman, LC, Loupe, PS, Silberstein, SD, Burstein, R, Ma, Y, Lipton, RB, Rapoport, AM, Dodick, DW, Bigal, ME, Yang, R

Lancet Neurol 2015
25297013 Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial

Smith, J, Kudrow, D, Silberstein, SD, Ashina, M, Lipton, RB, Kohrman, B, Kroll, R, Goadsby, PJ, Wilks, K, ALD403 study investigators, -, Dodick, DW, Olesen, J, Bargar, R, Hirman, J

Lancet Neurol 2014
29255900 Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial

Goadsby, PJ, Schacht, A, Dodick, DW, Camporeale, A, Oakes, TM, Zhang, Q, Carter, J, Ferguson, MB, Johnson, KW, Shan, Q, Martinez, J, Skljarevski, V

JAMA Neurol 2018
32145209 Medications Approved for Preventing Migraine Headaches

Ryan, M, Spindler, BL

Am. J. Med. 2020
Orthologous Events
Cite Us!